{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Respiratory+System+Agents&page=2", "query": { "condition": "Respiratory System Agents", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Respiratory+System+Agents&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T22:27:53.934Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04969315", "title": "TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Cancer", "Castrate Resistant Prostate Cancer", "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Colorectal Cancer (CRC)", "Endometrial Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "TT-10", "type": "DRUG" }, { "name": "TT-4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Portage Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2023-06-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 3, "location_summary": "Los Angeles, California • Louisville, Kentucky • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04969315" }, { "nct_id": "NCT06841055", "title": "Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-03-03", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Elizabethtown", "state": "Kentucky" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06841055" }, { "nct_id": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "T-DXd", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Volrustomig", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2021-03-09", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 13, "location_summary": "Duarte, California • Newport Beach, California • Orange, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04686305" }, { "nct_id": "NCT04924101", "title": "Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "Boserolimab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2021-07-15", "completion_date": "2025-06-23", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 14, "location_summary": "Gilbert, Arizona • Aurora, Colorado • Atlanta, Georgia + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04924101" }, { "nct_id": "NCT04104776", "title": "A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Diffuse Large B Cell Lymphoma", "Lymphoma, T-Cell", "Mesothelioma, Malignant", "Prostatic Neoplasms, Castration-Resistant", "Endometrial Cancer", "Ovarian Clear Cell Carcinoma", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Tulmimetostat", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2019-09-18", "completion_date": "2030-02-27", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 22, "location_summary": "Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04104776" }, { "nct_id": "NCT02857270", "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Melanoma", "Metastatic Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LY3214996", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2016-09-29", "completion_date": "2022-10-24", "has_results": false, "last_update_posted_date": "2022-11-22", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 8, "location_summary": "Washington D.C., District of Columbia • Sarasota, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02857270" }, { "nct_id": "NCT00000811", "title": "A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacterial Infections", "Pneumonia, Pneumocystis Carinii", "HIV Infections" ], "interventions": [ { "name": "Azithromycin", "type": "DRUG" }, { "name": "Atovaquone", "type": "DRUG" }, { "name": "Sulfamethoxazole-Trimethoprim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "18 Months", "sex": "ALL", "summary": "3 Months to 18 Months" }, "enrollment_count": 690, "start_date": null, "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000811" }, { "nct_id": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer", "Head and Neck Cancer", "Melanoma", "Gastric Cancer", "Renal Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "INBRX-106 - Hexavalent OX40 agonist antibody", "type": "DRUG" }, { "name": "pembrolizumab 200 mg", "type": "DRUG" }, { "name": "pembrolizumab 400 mg", "type": "DRUG" }, { "name": "Carboplatin AUC-5", "type": "DRUG" }, { "name": "Carboplatin AUC-6", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m2", "type": "DRUG" }, { "name": "Cisplatin 75mg/m2", "type": "DRUG" }, { "name": "Paclitaxel 200mg/m2", "type": "DRUG" }, { "name": "Nab paclitaxel 100mg/m2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 296, "start_date": "2019-12-10", "completion_date": "2027-05-12", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 30, "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198766" }, { "nct_id": "NCT06448754", "title": "Volrustomig Priming Regimens Exploratory Phase II Platform Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 180, "start_date": "2024-08-27", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 7, "location_summary": "Los Angeles, California • Grand Junction, Colorado • Wheat Ridge, Colorado + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06448754" }, { "nct_id": "NCT00451022", "title": "Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer", "Liver Cancer", "Breast Cancer", "Colon Cancer", "Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2004-09-13", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-07-23T22:27:53.934Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00451022" } ] }